Notes
see Reactions 1477 p3; 803095472
Reference
FDA. Potiga (ezogabine): Drug Safety Communication - FDA Determines 2013 Labeling Adequate to Manage Risks of Retinal Abnormalities, Potential Vision Loss, and Skin Discoloration. Internet Document : 16 Jun 2015. Available from: URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm451181.htm
Rights and permissions
About this article
Cite this article
Potential risk of Potiga-related vision loss can be managed. Reactions Weekly 1558, 6 (2015). https://doi.org/10.1007/s40278-015-2995-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-015-2995-2